Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors.
Article Details
- CitationCopy to clipboard
Rao MN, Lee GA, Grunfeld C
Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors.
Am J Infect Dis. 2006 Sep 30;2(3):159-166.
- PubMed ID
- 22162956 [ View in PubMed]
- Abstract
The use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors for the treatment of HIV infection and AIDS has been associated with multiple abnormalities in glucose and lipid metabolism. Specifically, these abnormalities include insulin resistance, increased triglycerides and increased LDL cholesterol levels. The metabolic disturbances are due to a combination of factors, including the direct effect of medications, restoration to health and HIV disease, as well as individual genetic predisposition. Of the available anti-retroviral medications, indinavir has been associated with causing the most insulin resistance and ritonavir with causing the most hypertriglyceridemia.
DrugBank Data that Cites this Article
- Pharmaco-metabolomics
Drug Drug Groups Metabolite Change Description Ritonavir Approved Investigational HDL cholesterol decreased Ritonavir decreases the level of HDL cholesterol in the blood Amprenavir Approved Investigational Total cholesterol increased Amprenavir increases the level of Total cholesterol in the blood Amprenavir Approved Investigational Triglycerides increased Amprenavir increases the level of Triglycerides in the blood Amprenavir Approved Investigational LDL cholesterol increased Amprenavir increases the level of LDL cholesterol in the blood Amprenavir Approved Investigational HDL cholesterol increased Amprenavir increases the level of HDL cholesterol in the blood Atazanavir Approved Investigational Total cholesterol increased Atazanavir increases the level of Total cholesterol in the blood Atazanavir Approved Investigational Triglycerides increased Atazanavir increases the level of Triglycerides in the blood Atazanavir Approved Investigational LDL cholesterol increased Atazanavir increases the level of LDL cholesterol in the blood Atazanavir Approved Investigational HDL cholesterol increased Atazanavir increases the level of HDL cholesterol in the blood Indinavir Approved LDL cholesterol increased Indinavir increases the level of LDL cholesterol in the blood Indinavir Approved Total cholesterol increased Indinavir increases the level of Total cholesterol in the blood Nelfinavir Approved Triglycerides increased Nelfinavir increases the level of Triglycerides in the blood Nelfinavir Approved LDL cholesterol increased Nelfinavir increases the level of LDL cholesterol in the blood Nelfinavir Approved Total cholesterol increased Nelfinavir increases the level of Total cholesterol in the blood Nevirapine Approved Total cholesterol increased Nevirapine increases the level of Total cholesterol in the blood Nevirapine Approved LDL cholesterol increased Nevirapine increases the level of LDL cholesterol in the blood Efavirenz Approved Investigational HDL cholesterol increased Efavirenz increases the level of HDL cholesterol in the blood Ritonavir Approved Investigational Total cholesterol increased Ritonavir increases the level of Total cholesterol in the blood Ritonavir Approved Investigational LDL cholesterol increased Ritonavir increases the level of LDL cholesterol in the blood Ritonavir Approved Investigational Triglycerides increased Ritonavir increases the level of Triglycerides in the blood Nevirapine Approved HDL cholesterol increased Nevirapine increases the level of HDL cholesterol in the blood Indinavir Approved Triglycerides increased Indinavir increases the level of Triglycerides in the blood Efavirenz Approved Investigational Total cholesterol increased Efavirenz increases the level of Total cholesterol in the blood